Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05649384
Other study ID # 2019-02269
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 1, 2020
Est. completion date September 30, 2025

Study information

Verified date December 2022
Source University Hospital, Basel, Switzerland
Contact Beate Hartmann, Msc PhD
Email Beate.Hartmann@usb.ch
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The PRESC1SE-MI study compares two algorithms for triage of patients presenting with chest pain and symptoms of heart attack (myocardial infarction) to the emergency department. Both algorithms are recommended by the European Society of Cardiology: the 0/3-hour algorithm and the 0/1-hour algorithm. Currently, most emergency departments worldwide use the 0/3-hour troponin algorithm. Cardiac troponin (cTn) is a heart-specific biomarker which indicates damage of the heart muscle and which increases after a heart attack. In the 0/3-hour algorithm, the amount of troponin in the bloodstream is measured with a high-sensitivity assay at admission and 3 hours thereafter. Likewise, the 0/1-hour algorithm means that the blood sample in which the troponin is measured is collected at admission and 1 hour later. Since recent clinical studies suggest that the 0/1-hour algorithm is superior to the 0/3-hour algorithm, many hospitals consider switching to the 0/1-hour algorithm. The aim of this study is to assess how feasible the time-saving 0/1-hour algorithm would be in reality and whether it provides the same accuracy and safety in the diagnosis of myocardial infarction as the current practice the 0/3-hour algorithm.


Recruitment information / eligibility

Status Recruiting
Enrollment 52156
Est. completion date September 30, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients aged 18 and above - Presentation with acute non-traumatic acute chest pain to the emergency department - Suspicion of acute myocardial infarction Exclusion Criteria: - Terminal kidney failure requiring dialysis - Cardiac arrest - Cardiogenic shock

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm
High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm
High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.

Locations

Country Name City State
Australia St Andrew's War Memorial Hospital Brisbane Brisbane
Austria Vienna General Hospital (AKH Wien) Wien
Finland University Central Hospital Helsinki Helsinki
Greece Attikon General Hospital Athens Athens
Italy Careggi University Hospital Florence Florence
Italy Azienda Ospedaliera San Giovanni Addolorata Roma
Italy Hospital Città della Salute e della Scienza di Torino Torino
Korea, Republic of Konkuk University Medical Center Seoul
Romania Emergency Institute for Cardiovascular Diseases C.C. Iliescu Bucharest
Spain Hospital Clinic Barcelona Barcelona
Spain University Hospital October 12 Madrid Madrid
Spain University Hospital Ramon y Cajal Madrid
Spain Hospital Clínico Universitario Valencia Valencia
Switzerland Kantonsspital Aarau Aarau
Switzerland St. Claraspital Basel
Switzerland Kantonsspital Luzern Luzern
Switzerland University Hospital Zurich Zürich
United Kingdom Leicester Royal Infirmary Leicester
United Kingdom Royal London Hospital London
United Kingdom Royal Cornwall Hospitals Treliske Truro
United States Baylor St. Luke's Medical Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Finland,  Greece,  Italy,  Korea, Republic of,  Romania,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite of all-cause mortality or new AMI (type 1) occurring within 30 days of index presentation Mortality rate and number of newly diagnosed AMI (type 1) in all enrolled patients 30 days
Primary Time from ED presentation to ED discharge or transfer Length of stay in the ED measured in hours 30 days
Secondary Proportion of patients managed as outpatients Number of patients who stay in hospital for index event less than 24 hours 24 hours
Secondary Readmission for suspected AMI within 30 days after index presentation Number of patients who stay in hospital for a new suspected AMI more than 24 hours within 30 days of index presentation 30 days
Secondary All-cause mortality at 30 days in all patients Number of deceased patients within 30 days after index presentation 30 days
Secondary All-cause mortality at 365 days in all patients Number of deceased patients within 365 days after index presentation 365 days
Secondary New AMI (type1) at 30 days in all patients Number of newly diagnosed AMI (type 1) in all patients within 30 days of index presentation 30 days
Secondary New AMI (type 1) at 365 days in all patients Number of newly diagnosed AMI (type 1) in all patients within 365 days of index presentation 365 days
Secondary Composite of all-cause mortality or new AMI (type 1) at 365 days after index presentation Mortality rate and number of newly diagnosed AMI (type 1) in all enrolled patients 365 days
Secondary Satisfaction of patients with their evaluation in the ED Satisfaction will be measured on a numerical/visual analogue scale from 0-100%, the higher the score, the greater the satisfaction 30 days
Secondary Treatment costs in the ED Costs of procedures performed in the ED will be calculated according to national remuneration systems 365 days
Secondary Length of stay in the ED Length of stay from admission to the ED to discharge or transfer will be calculated according to national remuneration systems 30 days
Secondary Feasibility of the 0/1-hour algorithm Feasibility defined as the percentage of patients in whom the "1h" blood draw is performed within 1h +/- 20 minutes from the "0h" blood draw 80 minutes
Secondary Effectiveness of rule-in Effectiveness defined as the time from presentation to coronary angiography in patients ultimately diagnosed with AMI (type 1) 30 days
Secondary Effectiveness of rule-out Effectiveness defined as time from presentation to discharge in patients ultimately diagnosed with non-cardiac disease 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT04951856 - Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI Phase 4
Completed NCT03103620 - Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
Completed NCT04648306 - Restore EF Observational Study
Recruiting NCT06095557 - MCG Discovery Study in Emergency Departments N/A
Not yet recruiting NCT04403048 - Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID N/A
Completed NCT03489603 - Clinical and Economic Outcomes of High Sensitivity Troponin for no ST Elevation Myocardial Infarction in Patients With Chest Pain in Emergency Departments in Italy-An Observational Study
Recruiting NCT04140019 - Early Cardiac Magnetic Resonance Imaging in Suspected Non-ST-Elevation Myocardial Infarction
Completed NCT04289012 - HELicobacter Pylori Screening in Patients With Acute Myocardial Infarction Pilot Study N/A
Active, not recruiting NCT03052036 - The British Heart Foundation SENIOR-RITA Trial N/A
Completed NCT02983123 - One-hour Troponin in a Low-prevalence Population of Acute Coronary Syndrome
Completed NCT03943966 - In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer N/A
Completed NCT03677180 - National Cardiogenic Shock Initiative
Completed NCT03507777 - ILUMIEN IV: OPTIMAL PCI N/A
Recruiting NCT03863327 - EKG Criteria and Identification of Acute Coronary Occlusion
Completed NCT03461484 - e-BioMatrix 6 Month DAPT France
Recruiting NCT03089450 - To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent N/A
Active, not recruiting NCT04090281 - Implementing Precision Medicine Approaches to Guide Anti-platelet Selection Phase 4
Recruiting NCT03562572 - FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease N/A
Completed NCT03822377 - Ticagrelor Administered as Standard Tablet or Orodispersible Formulation Phase 3
Recruiting NCT04002739 - PRedictOrs, PHEnotypes and Timing of Obstructive Sleep Apnea in Acute Coronary Syndrome N/A